Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

February 26, 2025

Dana-Farber

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Oncology
- Urology
- Cancer Biomarkers
#2

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Medical Oncology
- Cancer Biomarkers
- Translational Research
#3

MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Oncology
- Urologic Oncology
- Biomarker Research
#4

Johns Hopkins Hospital

Baltimore, MD
Key Differentiators
- Urology
- Oncology
- Cancer Biomarkers